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Background: The purpose of this research was to determine the acute and subacute safety and 
proof-of-concept efficacy of carbohydrate-derived fulvic acid (CHD-FA).
Methods: In this double-blind study, 30 male volunteers with predetermined atopy were ran-
domly assigned to either Group A or Group B, each consisting of 15 participants. In part 1 of 
the study, the groups were administered increasing amounts of CHD-FA, ranging from 5 mL to 
40 mL, provided that no adverse events had occurred at the previous dosage. In part 2, Group A 
participants received 20 mL of 3.8% CHD-FA twice daily for 3 days and were monitored for a 
week. Because no adverse events occurred, Group B received 40 mL of 3.8% CHD-FA twice 
daily for a period of 3 days. In part 3, both groups received either 40 mL of 3.8% CHD-FA or 
placebo twice daily for a period of one week, followed by a one-week washout period before 
crossover to the alternative treatment schedule. Parameters used to establish safety were electro-
cardiography, a physical examination, a health questionnaire, and hematology and bio  chemistry, 
determined at baseline, during regular calculated intervals, and at the end of each part of the 
study. A skin prick test was done as part of the screening process and, from the result, the allergen 
the participant was most allergic to was then selected, along with the positive histamine and 
negative control to be repeated at the start and end of each respective stage.
Results: Safety parameters remained constant throughout the trial. A significant decrease in 
skin prick test results was observed.
Conclusion: No severe adverse events occurred, establishing that CHD-FA to be safe at doses 
up to 40 mL twice daily for a week and that at this dosage CHD-FA acts as an anti-inflammatory 
agent. These findings confirm earlier animal data.
Keywords: CHD-FA, safety, efficacy, anti-inflammatory
Introduction
Humic substances
Humic substances are present wherever organic matter is being decomposed,1 and can 
be defined as “… a general category of naturally occurring, biogenic, heterogeneous 
organic substances that can generally be characterized as being yellow to black in color 
and of high molecular weight”. Humic acids are found in soils, waters, sewage, compost 
heaps, marine and lake sediments, peat bogs, carbonaceous shales, lignites, and brown 
coals. Humic substances can be subdivided into humic acid, fulvic acid, and humin. 
The average molecular weight of humic substances may range from 500 to 5000 Da 
for fulvic acid to 3000 to 1,000,000 Da for humic acid.2
The Department of Pharmacology at the University of Pretoria has been involved 
in researching the novel medicinal properties and applications of humic acid and 
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f  ulvic acid since 2000. Oxifulvic acid, so-called because it is 
derived from controlled wet oxidation of carbon-containing 
coal, was used for topical application research.3,4 Fulvic 
acid 4.5% and 9% showed equivalence when compared 
with diclofenac sodium 1% and betamethasone 0.1% in a 
murine model when applied topically to suppress a cutaneous 
inflammatory response, and found to have none of the adverse 
effects seen with the aforementioned anti-inflammatory 
agents.3 In feline and canine models, fulvic acid showed anti-
inflammatory properties by inhibiting the accumulation of 
pus in pyotraumatic dermatitis when applied topically.5
Carbohydrate-derived fulvic acid (CHD-FA) is a new 
heavy metal-free carbohydrate-derived fulvic acid. In a topi-
cal toxicity and sensitization study, 60 6–8-week-old female 
Balb C mice were used. The mice were randomized into three 
groups consisting of 20 mice per group. Group 1 received 
ung emulcificans aqueosum (UEA) only, Group 2 received 
CHD-FA, and Group 3 received CHD-FA neutralized to a 
pH of 5.5. From day 8, they received the products topically 
on the left ear twice a day for 30 days (up to 38 days). The 
amount of CHD-FA preparation used was calculated using 
8 mg CHD-FA/mouse, or 400 mg/kg body weight, twice a 
day. Morbidity was determined on a daily basis by evalua-
tion of reduced food and water intake resulting in weight loss 
(more than 20% original weight), observation of abnormal 
movement (particularly pertaining to the ability of the ani-
mal to obtain food and water), and ease of breathing. Blood 
samples (500 µL/mouse) were drawn after termination at the 
end of the study to determine kidney and liver enzyme levels 
(creatinine and gamma-glutamyl transferase, respectively). 
Analysis of variance was used to analyze data. The data 
suggested that the CHD-FA, when applied topically, did not 
produce any hypersensitivity reactions and was nontoxic with 
regards to liver and kidney function in mice over a period 
of one month (data on file, Department of Pharmacology, 
University of Pretoria).
A 30-day toxicity study was done using 60 female 
6–8-week old Sprague-Dawley rats. Animals in the 
experimental group (n = 20) received a single oral dose 
(by gavage) of 100 mg/kg body weight/day of CHD-FA 
(potassium salt) neutralized to a pH of 5.5 in distilled water 
as a 1.0 mL bolus per day for 90 days. Control animals 
(n = 20) received an oral dose (by gavage) of 1.0 mL dis-
tilled water per day to control for the procedure used in the 
experimental group. A third group of 20 animals was added 
and received half the dose of the experimental group. The 
animals were weighed daily and monitored for pain and 
distress (behavioral changes).
Toxicity was determined by evaluation of reduced food 
and water intake resulting in weight loss, observation of 
abnormal movement, and ease of breathing. Blood samples 
(500 µL/rat) were drawn from the animals at the beginning 
and end of the study for hematological analysis and kidney 
and liver enzyme levels. The data suggested that the product 
was nontoxic with regards to liver and kidney function in rats 
over a period of 6 months, when administered orally.6
In healthy volunteers, fulvic acid had no significant effect 
on safety parameters and did not induce sensitization when 
applied topically. Fulvic acid cream 4.5% caused inhibition of 
the elicited inflammatory reaction, and this was comparable 
with hydrocortisone.2 A new product with a lower metal 
content was developed for systemic application. An investi-
gation of the safety of this product administered by gavage 
in rats (175 mg/kg) was performed. The rats showed no sign 
of discomfort, and results obtained from blood specimens 
sent to Clinical Pathology Laboratories indicated that the 
CHD-FA administered systemically for a period of 6 weeks 
was indeed safe.6
The in vivo human data demonstrating topical efficacy 
and safety as well as significant animal data supporting 
in vivo efficacy and safety after systemic use, as well as 
observational data confirming safety of oral administration 
of this complimentary or alternative medicine in humans 
motivated this in vivo safety study. The aim of this research 
was to establish the acute and subacute safety of CHD-FA 
over the anticipated dose range and also to determine if 
CHD-FA potentially has anti-inflammatory properties that 
would w arrant further investigation.
Materials and methods
In this double-blind study, 30 male volunteers with predeter-
mined atopy were randomly assigned to Group A or Group B 
on arrival by random allocation of an alpha numeric, eg, A06 
or B11 from a computer-randomized list, each consisting of 
15 participants. The participants were recruited into the study 
after approval was obtained from the University of Pretoria 
research ethics committee.
Part 1: acute exposure safety
A one-off oral dosage of either 5 mL and 20 mL or 10 mL and 
40 mL (3.8%) CHD-FA was administered and the volunteers 
were monitored at various intervals for 72 hours, with a final 
visit 7 days after oral dosage, with the following parameters 
being monitored: vital parameters, clinical investigation, 
patient perception of general health questionnaire, electrocar-
diography, and hematology and biochemistry, including full 
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blood count and liver and kidney function. After s  uccessful 
completion of part 1, ie, no adverse events that were of 
c  linical relevance, part 2 was commenced.
Part 2: subacute toxicity
This was a 3-day exposure in the same volunteers, ie, 20 mL or 
40 mL of 3.8% CHD-FA was administered twice per day, with 
the following parameters being monitored at various intervals: 
vital parameters, clinical investigation, patient pe  rception of gen-
eral health, electrocardiography, hem  atology and biochemistry, 
including full blood count and liver and kidney function. After 
successful completion of part 2, ie, no adverse events that were 
of clinical relevance, part 3 was commenced.
Part 3: proof of concept
This was a 7-day exposure in the same volunteers, ie, 40 mL 
of 3.8% CHD-FA or placebo administered twice per day, 
followed by a two-week washout period and subsequent cross-
over, with the following parameters being   monitored at various 
intervals: skin pricks, vital parameters,   clinical investigation, 
patient perception of general health,   electrocardiography, and 
hematology and biochemistry, including full blood count 
and liver and kidney function. For each participant, the skin 
prick test was done as part of the screening process and from 
the result the allergen to which the   participant was most 
allergic was then selected along with the positive histamine 
and negative control to be repeated at the start and end of 
each respective stage. Wheals were measured using a digital 
caliper 10 minutes after exposure.
Outcomes
Outcomes included safety, assessed by clinical parameters 
and vitals. Biochemistry included urea, uric acid, creatinine, 
chloride, potassium, sodium, gamma-glutamyl transferase, 
alkaline phosphatase, aspartate aminotransferase, and alanine 
aminotransferase. Hematology included a full blood count and 
differential, with hemoglobin and white and red blood cells. All 
biochemistry and hematology measurements were done in an 
ISO (International Organization for Standardization) accred-
ited laboratory using a Roche P800 and Siemens Advia 2120, 
respectively. Electrocardiograms were read by an independent 
clinician who reported on changes from baseline. Proof of 
concept was determined as a significant (P , 0.05) reduction 
in size of wheal formation post CHD-FA treatment.
inclusion criteria
Male patients aged 18 years and older who had a pollen 
allergy and were not on antiallergic treatment were recruited 
into the study. Patients gave their written informed consent. 
Patients were otherwise healthy with no other systemic disease 
that could influence the immune response. N  ormal hematol-
ogy and biochemistry values, electrocar  diograms, and clinical 
investigations were confirmed before randomization.
Exclusion criteria
Women and subjects with systemic diseases, such as   diabetes 
mellitus, kidney failure, liver failure, or autoimmune, hema-
tologic, psychiatric, gastrointestinal, cardiovascular, or lung 
disease that could significantly compromise health were 
excluded. Any immune system disease other than atopy was 
also an exclusion criterion, as were an inability to understand 
or give written informed consent, any abnormality in hema-
tology or biochemistry values, alcoholism or drug addiction, 
and any type of immunosuppressant therapy.
Treatment
In the acute toxicity study, Group A received 5 mL and 20 mL 
of CHD-FA 3.8% in syrup as single doses and Group B received 
10 mL and 40 mL of CHD-FA 3.8% as a single dose. In the 
subacute toxicity study, Group A received 20 mL of CHD-FA 
3.8% twice daily for 3 days and Group B received 40 mL of 
CHD-FA 3.8% twice daily for a 3-day period. For proof of 
c  oncept, both groups received either 40 mL of CHD-FA 3.8% or 
placebo for a 7-day period, followed by a 7-day washout period, 
then a crossover. All treatments were taken without food.
Statistical analysis
The results were analyzed using GraphPad Prism 4.0. The 
Wilcoxon rank test was used for the safety aspects of the 
study. For the proof of concept results, an analysis of cova-
riance was used, with P , 0.05 regarded as statistically 
significant when comparing the before and after results of 
the treated versus placebo groups, respectively.
Results
Twenty-one participants successfully completed the trial, one 
failed to comply after screening, one failed to comply at the first 
visit, one experienced an adverse event (namely hypertension 
which appeared to be unrelated to the study   medication), and 
two subjects failed to comply during part 1 of the study. Four 
subjects were withdrawn as a result of either an   arrhythmia or 
bradycardia that was present at baseline.
Safety
All safety parameters remained within normal limits for the 
duration of the acute phase of the trial, with only one subject 
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having elevated aspartate aminotransferase and alanine 
aminotransferase levels after 40 mL dosing, which was more 
likely to be associated with a viral infection rather than a side 
effect of the CHD-FA. These values did return to within normal 
limits. Due to the vast amount of testing done, the parameters 
of interest are tabulated below, illustrating the battery of tests 
used to determine safety, namely liver function (Figure 1) and 
kidney function (Figures 2 and 3), respectively.
Efficacy
With statistical analysis, using analysis of variance and 
adjusting for baseline, a significant difference was observed, 
with P , 0.05 when comparing the before and after results of 
the treated versus placebo groups, respectively; 81% of the 
participants had a decreased wheal after CHD-FA treatment 
versus 62% of those treated with placebo (Table 1). Because 
there is no known method of detecting plasma levels of fulvic 
acid compounds,   clinical outcome served as evidence of sys-
temic exposure, ie, absorption. Side effects were monitored, 
and are summarized in Figure 4.
Discussion
Safety
With extensive safety testing, indicated by hematology 
and biochemistry markers, it can be stated with co  nfidence 
that safety parameters were not affected in any way, 
demonstrating that the dose range of CHD-FA tested cor-
related well with that of the rat studies, in which no signifi-
cant fluctuations in safety parameters were observed after 
9 months of dosing.4
Efficacy
Comparing wheal measurements (an inflammatory 
response to an allergen), there was a significant difference 
between CHD-FA and placebo, ie, wheal measurements 
decreased significantly on CHD-FA, demonstrating that 
CHD-FA has a measurable in vivo effect on immediate 
hypersensitivity and warranting further investigations into 
the anti-inflammatory effect as well as the mechanism 
of action.
Side effects
The only noteworthy side effects were diarrhea, headache, 
and a sensation of a burnt or sore throat, all likely attribut-
able to the low pH of the CHD-FA administered orally (the 
manufacturer’s recommendation is to dilute the product in 
juice or water). The majority of these side effects occurred 
after ingestion of the upper limit of the CHD-FA dose range, 
ie, 40 mL twice daily. These side effects were not severe, and 
mostly subsided after a short period of time or after ingestion 
of food. The diarrhea resolved without medical intervention. 
After clinical review, the panel’s decision was that the side 
0
10
20
30
40
50
60
70
80
Baseline
Final
ALTA ST Alk Phos Gamma GT
U
/
L
Figure 1 Liver function tests.
Abbreviations: ALT, alanine transaminase; AST, aspartate transminase; Alk Phos, 
alkaline phosphatase; Gamma GT, gamma glutamyl transpeptidase.
0
50
100
150
Baseline
Final
Sodium Chloride
m
m
o
l
/
L
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Figure 3 Kidney function tests.
Table 1 Measurements of wheal diameter before and after in 
treated versus placebo groups with respect to skin prick tests
Diameter of wheal (mm)
Before After
Mean SD Mean SD
CHD-FA 6.63 3.64 4.97* 3.26
Placebo 7.03 4.15 6.73 3.98
Note: *P , 0.05.
Abbreviations: SD, standard deviation; CHD-FA, carbohydrate-derived fulvic acid.
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effects observed were mild and transient, and not causally 
linked to CHD-FA.
Conclusion
No severe adverse events occurred, demonstrating CHD-FA 
to be safe at the dose tested. There was a significant decrease 
in wheal formation in the skin prick test, confirming that 
CHD-FA acts as an inhibitor of the immediate hypersensitiv-
ity reaction and that the product is systemically available. 
In light of the data from this research and previous toxicity 
studies, it can be stated that a 15 mL daily dose of CHD-FA 
diluted in water or juice, as recommended by the manufac-
turer, can be used safely.
Disclosure
The authors report no conflicts of interest in this work.
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Figure 4 Side effects reported on CHD-FA. 
Abbreviations: bid, twice daily; CHD-F, carbohydrate-derived fulvic acid.
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